AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02104804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Saxagliptin
Description: Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
Study NCT01432197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADL intervention
Description: 1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
Study NCT05272527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition to Motherhood Program
Description: Transition to Motherhood program includes 5 sessions. The first session covers the pregnancy process, the second session deals with the birth process, the third session deals with the postpartum period, the fourth session deals with infant care, and the fifth session deals with breast milk and breastfeeding and immunity. Trainings are online. In addition to the lecture technique, the training includes auxiliary techniques such as models, videos, case studies, training cards, and applied demonstrations. The program was completed by telephone follow-up in the first and fourth weeks postpartum.
Study NCT00717366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: Will be administered IV, every 4 weeks.
Study NCT02695706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laboratoires Mercurochrome Reparador
Description: Developed for the treatment of damaged or fragile skin.
Study NCT03936816 — intervention group
Intervention type: OTHER
Intervention: GBS vaginal double swab
Description: The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
Study NCT02200471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeinViewer
Study NCT01463865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
Study NCT01463865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
Study NCT01003080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquamantys Device
Description: The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
Study NCT01003080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment for hemostasis during a total knee arthroplasty.
Description: The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device.
Study NCT01173341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
Study NCT00152126 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan, Melphalan
Description: Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
Study NCT04019002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C Pyruvate
Description: Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suicide risk
Description: MADRS (10) and HAM-D (3)
Study NCT01173341 — intervention group
Intervention type: OTHER
Intervention: Blood Collection
Description: Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
Study NCT01173341 — intervention group
Intervention type: OTHER
Intervention: Symptoms Questionnaire
Description: Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
Study NCT02612961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3mL of normal saline from the pink sodium chloride bullet
Study NCT02612961 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator of 3mL normal saline
Study NCT01804322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized educational plan
Description: The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~* The cause and nature of the adverse event and/or drug interaction~* The tolerability profile of each drug present in the schedule~* The clinical manifestations associated with the current drug interactions~* Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~* The reasons for and the potential benefits of the suggested treatment change~* An encouragement to withdraw any potentially interfering or contraindicated drug
Study NCT01804322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care according to the participating Epilepsy Centers
Study NCT00848549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
Study NCT00848549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
Study NCT03779035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2
Study NCT03779035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1250mg/m2
Study NCT03779035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250mg/m2
Study NCT02860806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: 3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suicide risk
Description: MADRS (10) and HAM-D (3)
Study NCT00489281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Depression thoughts
Description: EPD
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression thoughts
Description: EPD
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life and disability
Description: Quality of life and disability
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life and disability
Description: Quality of life and disability
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical and epidemiological factors
Description: Variables and categories
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and epidemiological factors
Description: Variables and categories
Study NCT04234776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Safety of ketamine IM
Description: Vital signs
Study NCT04234776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safety of ketamine IM
Description: Vital signs
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tolerability of ketamine IM
Description: UKU-SERS, YOUNG, CADSS and BPRS-12.
Study NCT04234776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tolerability of ketamine IM
Description: UKU-SERS, YOUNG, CADSS and BPRS-12.
Study NCT00839241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bellovac ABT
Description: Bellovac ABT (autologous blood)
Study NCT00839241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogenic Blood Transfusion
Description: Transfusion of allogenic (bank) blood.
Study NCT03668288 — intervention group
Intervention type: OTHER
Intervention: Data record and questionnaires passation
Description: Data record and questionnaires passation (SF36)
Study NCT02754999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SANGUINATE™
Description: As needed (PRN) infusions of 500 mL of SANGUINATE
Study NCT03014973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra-prostatic concentration of sexual steroids
Study NCT02860806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of matching placebo.
Study NCT00489281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2/day IV on Days -6, -5, -4, -3, and -2.
Study NCT00489281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.
Study NCT00489281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.
Study NCT00489281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant
Description: An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
Study NCT03014973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-rectal biopsy
Study NCT03645772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: 12-week progressive training intervention
Study NCT03645772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Description: 12-week progressive training intervention
Study NCT01268813 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Breath analysis and blood analysis
Description: Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
Study NCT01268813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath analysis and blood analysis
Description: Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
Study NCT01348425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Longer Zilver PTX Stents
Description: Treatment with at least one 100 mm or longer Zilver PTX stent
Study NCT01348425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shorter Zilver PTX Stents
Description: Treatment with Zilver PTX stents 80 mm or shorter only
Study NCT03321214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten Sensor Dose-Finding Intervention
Description: Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is \< 20 ppm or a wheat icon for > 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants.
Study NCT03522272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic cleaning
Description: Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride
Study NCT03522272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic cleaning
Description: Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water
Study NCT03522272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional denture hygiene
Description: Mechanical cleaning of denture with a soft toothbrush and liquid detergent
Study NCT01892618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: 13-valent pneumococcal conjugated vaccine
Study NCT01892618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax
Description: 23-valent pneumococcal polysaccharide vaccine
Study NCT00702156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
Study NCT00702156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
Study NCT04198103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transperineal Focal Laser Ablation (TPLA)
Description: The intervention will take place in an ambulatory setting using EchoLaser system. The treatment consists of the trasmission of laser energy into the tissue through the percutaneous insertion of optical fiber under local anesthesia. Within each needle, an optic fiber of 300 µm will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 3W. At the end of the first ablation there is a pull-back of about 1 cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used for a total duration of about 30minutes. At the end of the treatment corticosteroid is given for anti-edema and anti-inflammatory effects and Antibiotic therapy and gastroprotective therapy is given. After an adequate amount of time for observation, the patient is dismissed.
Study NCT02940717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita suprinity
Description: New glass ceramic material
Study NCT02940717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emax CAD
Description: standard etchable glass ceramic used for laminate venneers
Study NCT00681538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
Study NCT00681538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Study NCT04105244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training©
Description: The intervention includes self-help and help-seeking skills.
Study NCT01745991 — intervention group
Intervention type: DEVICE
Intervention: CoSeal spray
Study NCT00975195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium inhalation
Study NCT00975195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Study NCT00975195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Study NCT00975195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo matched for fluticasone propionate
Study NCT00780169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib + FOLFIRI
Description: escalating doses of sorafenib and irinotecan~* sorafenib starting dose 400 mg/day~* irinotecan starting dose 80 mg/m2 on day 1
Study NCT00394290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Pressure
Description: Nighttime continuous positive pressure device, to be used every day
Study NCT00634959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
Study NCT00634959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 100 mg oral tablet once daily while fasted on Days 1-10
Study NCT00489281 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation - 200
Description: 200 centigray (cGy) in one fraction on Day -1.
Study NCT00634959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 300 mg oral tablet once daily while fasted on Days 1-10
Study NCT00634959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
Study NCT00634959 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablet on Days 1-10 (fed and fasted)
Study NCT00717262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQK-1001
Description: HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
Study NCT00717262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo capsules administered once a day, orally, for 14 days.
Study NCT04191577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424 Low Dose
Description: CVN424
Study NCT04191577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424 High Dose
Description: CVN424
Study NCT04191577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00790738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine (T3)
Description: liothyronine (T3) up to 50 micrograms a day
Study NCT00790738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04757909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monthly Haemoglobinometry
Description: Monthly measurement of capillary hemoglobin with non-invasive techniques in primary health care.~Inclusion in a transfusion circuit with referral to a hospital day hospital if necessary.
Study NCT00668304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin 400 mg once orally daily
Study NCT05181020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Voice Exposure
Description: Main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.
Study NCT03365479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
Study NCT04143672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic digital pressure algometer
Description: Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer.
Study NCT04143672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pain sensitivity questionnaire
Description: Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
Study NCT01485926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Carboplatin and Trastuzumab
Description: 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.